financetom
Business
financetom
/
Business
/
Canada's Topaz Energy Q3 adjusted net income rises 
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Canada's Topaz Energy Q3 adjusted net income rises 
Nov 3, 2025 2:16 PM

(Corrects currency to C$ in bullets 2 & 3 of Outlook)

Overview

* Energy royalties firm Topaz Q3 2025 royalty production grows 15% yr/yr, driven by acquisitions

* Free cash flow for Q3 2025 rises 7% per share from last year

* Topaz completes NEBC Montney acquisition, aligning with Tourmaline's growth plans

Outlook

* Topaz reconfirms 2025e guidance of 21,000-23,000 boe/d royalty production

* Company expects 2025 processing revenue between C$88 mln and C$92 mln

* Topaz anticipates exiting 2025 with net debt between C$500 mln and C$510 mln

Result Drivers

* ROYALTY PRODUCTION GROWTH - Topaz reports a 15% increase in Q3 2025 royalty production, driven by acquisitions and higher natural gas and oil production

* ACQUISITION IMPACT - Completion of NEBC Montney acquisition aligns Topaz with Tourmaline's growth plans, enhancing future growth prospects

* OPERATIONAL EFFICIENCIES - Reduced operating expenses and hedging gains contribute to increased free cash flow margin

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 C$16.12

Adjusted mln

Net

Income

Q3 Capex C$1.86

mln

Q3 C$81.41

EBITDA mln

Q3 Free C$72.98

Cash mln

Flow

Q3 Net C$535.41

Debt mln

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 11 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the oil & gas exploration and production peer group is "buy"

* Wall Street's median 12-month price target for Topaz Energy Corp ( TPZEF ) is C$31.00, about 19.7% above its October 31 closing price of C$24.90

* The stock recently traded at 43 times the next 12-month earnings vs. a P/E of 45 three months ago

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Merus Says Target Tumors in Lung Cancer Patients Decrease in Size After MCLA-129 Treatment
Merus Says Target Tumors in Lung Cancer Patients Decrease in Size After MCLA-129 Treatment
Jun 3, 2024
05:13 PM EDT, 06/03/2024 (MT Newswires) -- Merus (MRUS) said Monday that its MCLA-129 product candidate demonstrated a reduction in target lesion tumor size in 80% of patients with certain types of non-small-cell lung cancer who were available for evaluation after two or more treatments. Of the 22 patients treated as of the Feb. 16 cutoff date, 15 were available...
Construction Partners Closes Hudson Paving Acquisition
Construction Partners Closes Hudson Paving Acquisition
Jun 3, 2024
05:14 PM EDT, 06/03/2024 (MT Newswires) -- Construction Partners ( ROAD ) said late Monday that it closed the acquisition of Hudson Paving, adding a hot-mix asphalt plant and related crews and equipment serving the Sandhills region of North Carolina. Price: 57.50, Change: +0.12, Percent Change: +0.21 ...
Ebay Insider Sold Shares Worth $402,110, According to a Recent SEC Filing
Ebay Insider Sold Shares Worth $402,110, According to a Recent SEC Filing
Jun 3, 2024
05:16 PM EDT, 06/03/2024 (MT Newswires) -- Julie A Loeger, Senior Vice President, Chief Growth Officer, on May 31, 2024, sold 7,419 shares in Ebay ( EBAY ) for $402,110. Following the Form 4 filing with the SEC, Loeger has control over a total of 70,797 shares of the company, with 70,797 shares held directly. SEC Filing: https://www.sec.gov/Archives/edgar/data/1065088/000106508824000099/xslF345X03/wk-form4_1717448773.xml ...
Legend Biotech Says Phase 2 Trial of Carvykti to Treat Multiple Myeloma Showed 'Deep, Durable' Responses
Legend Biotech Says Phase 2 Trial of Carvykti to Treat Multiple Myeloma Showed 'Deep, Durable' Responses
Jun 3, 2024
05:17 PM EDT, 06/03/2024 (MT Newswires) -- Legend Biotech ( LEGN ) said late Monday data from the phase 2 CARTITUDE-2 cohort D study in people with multiple myeloma showed that patients with a less-than-complete response after autologous stem cell transplant had deep and durable responses after a single infusion of Carvykti. We are conducting phase 3 studies to determine...
Copyright 2023-2026 - www.financetom.com All Rights Reserved